Oorsprong van het eerstegraads netwerk van Jason Carlton
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Public Company | Financial Conglomerates | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Jason Carlton via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal | |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Biotechnology | Corporate Officer/Principal | |
INCYTE CORPORATION | Pharmaceuticals: Major | Corporate Officer/Principal | |
PONIARD PHARMACEUTICALS, INC. | Biotechnology | Chief Executive Officer | |
ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
HUMANIGEN, INC. | Biotechnology | Chairman | |
George Washington University | College/University | Doctorate Degree | |
Yale University | College/University | Undergraduate Degree | |
PLUS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Cetya Therapeutics, Inc.
Cetya Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cetya Therapeutics, Inc. engages in the commercialization of histone deacetylase inhibitors based on largazole. Its histone deacetylase inhibitors analog has bifunctional modifications and the potential to target specific cell types or tumors. The company was founded by John Pilon in 2012 and is headquartered in Fort Collins, Co. | Pharmaceuticals: Major | Founder | |
Nuvelution Pharma, Inc.
Nuvelution Pharma, Inc. BiotechnologyHealth Technology Nuvelution Pharma, Inc. provides solutions for R&D companies in the pharmaceutical and biotech industries. The firm leverages its knowledge, experience and relationships in the Pharma and Biotech industries to deploy capital in risk-sharing collaborations with companies where product development can be facilitated by both capital and human resources, making this model an essential tool for pharma and biotech companies to bring products to the market. The company was founded by Sanford S. Zweifach and is headquartered in South San Francisco, CA. | Biotechnology | Chief Executive Officer | |
NEXTCURE, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Orca Biosystems, Inc.
Orca Biosystems, Inc. Medical SpecialtiesHealth Technology Orca Biosystems, Inc. engages in empowering cell therapies by precisely engineering bone marrow transplants (BMT) using rapid clinical cell sorting of human grafts. The company was founded by Nathaniel fernhoff and Ivan K. Dimov and is headquartered in Mountain View, CA. | Medical Specialties | Founder | |
Encellin, Inc.
Encellin, Inc. Medical SpecialtiesHealth Technology Encellin, Inc. provides transplant to address chronic diseases. It focuses on type 1 diabetes. The company was founded by Grace Wei, Ronald Martell, and Crystal Nyitray and is headquartered in San Francisco, CA. | Medical Specialties | Founder | |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | Biotechnology | Founder | |
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Biotechnology | Director/Board Member | |
Kalobios Pharmaceuticals, Inc. | Chairman |
Statistieken
Internationaal
Verenigde Staten | 20 |
Verenigd Koninkrijk | 2 |
Sectoraal
Health Technology | 17 |
Consumer Services | 3 |
Commercial Services | 2 |
Operationeel
Director/Board Member | 8 |
Chief Executive Officer | 7 |
Chairman | 5 |
President | 5 |
Founder | 5 |
Sterkste connecties
Insiders | |
---|---|
Ronald Martell | 16 |
Kevin N. Heller | 6 |
- Beurs
- Insiders
- Jason Carlton
- Bedrijfsconnecties